Drugs that contain Ponesimod
1. Drug name - PONVORY
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE43728 | JANSSEN PHARMS | Thiazolidin-4-one derivatives |
Nov, 2024
(2 years from now) | |
| US9062014 | JANSSEN PHARMS | Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one |
May, 2032
(9 years from now) | |
| CN100567275C | JANSSEN PHARMS | As Immunosuppressive Agents 5 - (Phenyl - (Z) - Ylidene)--4 - Ketone Derivative |
Nov, 2023
(1 year, 1 month from now) | |
| CN1882555A | JANSSEN PHARMS | As Immunosuppressant 5 - (Phenyl - (Z) - Subyl) - Thiazole - -4 - Ketone Derivative |
Nov, 2023
(1 year, 1 month from now) | |
| CN102177144A | JANSSEN PHARMS | Crystalline Forms Of (R)-5-[3-Chloro-4-(2,3-Dihydroxy-Propoxy)-Benz[Z]Ylidene] -2- ([Z]-Propylimino) -3-O-Tolyl-Thiazolidin-4-One |
Oct, 2029
(7 years from now) | |
| CN102177144B | JANSSEN PHARMS | (R)-5-[3-Chloro--4-(2, 3-Dihydroxy-Propoxy)-Benzo [Z] Subunit]-2-([Z]-Propyl)--3-O-Tolyl--4-Ketone Of Crystal Form |
Oct, 2029
(7 years from now) | |
| IN254201B | JANSSEN PHARMS | Novel Thiazolidin-4-One Derivatives |
Nov, 2024
(2 years from now) | |
| IN200602225P4 | JANSSEN PHARMS | Novel Thiazoldin-4-One Derivatives |
Nov, 2024
(2 years from now) | |
| EP1689726A1 | JANSSEN PHARMS | 5-(Benz- (Z) -Ylidene) -Thiazolidin-4-One Derivatives As Immunosuppressant Agents |
Nov, 2024
(2 years from now) | |
| EP1689726B1 | JANSSEN PHARMS | 5-(Benz- (Z) -Ylidene) -Thiazolidin-4-One Derivatives As Immunosuppressant Agents |
Nov, 2024
(2 years from now) | |
| EP2344465B1 | JANSSEN PHARMS | Crystalline Forms Of (R) -5- [3-Chloro-4-( 2, 3-Dihydroxy-Propoxy)-Benz [Z]Ylidene]-2- [Z]-Propylimino) -3-O-Tolyl-Thiazolidin-4-One |
Oct, 2029
(7 years from now) | |
| EP2344465A1 | JANSSEN PHARMS | Crystalline Forms Of (R) -5- [3-Chloro-4-( 2, 3-Dihydroxy-Propoxy)-Benz [Z]Ylidene]-2- [Z]-Propylimino) -3-O-Tolyl-Thiazolidin-4-One |
Oct, 2029
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9000018 | JANSSEN PHARMS | Thiazolidin-4-one-derivatives |
Nov, 2024
(2 years from now) | |
| US8273779 | JANSSEN PHARMS | Thiazolidin 4-one derivatives |
Dec, 2025
(3 years from now) | |
| US10220023 | JANSSEN PHARMS | Dosing regimen for a selective S1P1 receptor agonist |
Dec, 2035
(13 years from now) | |
Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults using a dose titration schedule followed by a maintenance dose
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 2MG | TABLET;ORAL | Prescription |
| 3MG | TABLET;ORAL | Prescription |
| 4MG | TABLET;ORAL | Prescription |
| 5MG | TABLET;ORAL | Prescription |
| 6MG | TABLET;ORAL | Prescription |
| 7MG | TABLET;ORAL | Prescription |
| 8MG | TABLET;ORAL | Prescription |
| 9MG | TABLET;ORAL | Prescription |
| 10MG | TABLET;ORAL | Prescription |
| 20MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.